BCL2L1 and myeloid leukemia: found that the combination of PI3K/mTOR inhibitors (BEZ235, PI-103, etc.)and BCL-2/BCL-XL inhibitors significantly reduces BAX/BAK binding to MCL-1, BCL-2 or BCL-XL in human myeloid leukemia cells, which also indirectly restores the drug treatment effect.